Ultimovacs ASA Financials
| ULTI Stock | NOK 2.07 0.02 0.98% |
Ultimovacs |
Understanding current and past Ultimovacs ASA Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ultimovacs ASA's financial statements are interrelated, with each one affecting the others. For example, an increase in Ultimovacs ASA's assets may result in an increase in income on the income statement.
Ultimovacs ASA Stock Summary
Ultimovacs ASA competes with Bergenbio ASA, and PCI Biotech. Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.| Foreign Associate | USA |
| Instrument | Norway Stock View All |
| Exchange | Oslo Stock Exchange |
| ISIN | NO0010851603 |
| Business Address | Ullernchaussen 64, Oslo, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | ultimovacs.com |
| Phone | 47 41 38 00 80 |
| Currency | NOK - Kroner |
You should never invest in Ultimovacs ASA without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Ultimovacs Stock, because this is throwing your money away. Analyzing the key information contained in Ultimovacs ASA's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Ultimovacs ASA Key Financial Ratios
There are many critical financial ratios that Ultimovacs ASA's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Ultimovacs ASA reports annually and quarterly.Ultimovacs Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ultimovacs ASA's current stock value. Our valuation model uses many indicators to compare Ultimovacs ASA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ultimovacs ASA competition to find correlations between indicators driving Ultimovacs ASA's intrinsic value. More Info.Ultimovacs ASA is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ultimovacs ASA's earnings, one of the primary drivers of an investment's value.Ultimovacs ASA Systematic Risk
Ultimovacs ASA's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ultimovacs ASA volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Ultimovacs ASA correlated with the market. If Beta is less than 0 Ultimovacs ASA generally moves in the opposite direction as compared to the market. If Ultimovacs ASA Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ultimovacs ASA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ultimovacs ASA is generally in the same direction as the market. If Beta > 1 Ultimovacs ASA moves generally in the same direction as, but more than the movement of the benchmark.
Ultimovacs ASA November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ultimovacs ASA help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ultimovacs ASA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ultimovacs ASA based on widely used predictive technical indicators. In general, we focus on analyzing Ultimovacs Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ultimovacs ASA's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 50.89 | |||
| Value At Risk | (6.49) | |||
| Potential Upside | 6.55 |
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.